2020
Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B
Chiale C, Yarovinsky TO, Mason SW, Madina BR, Menon M, Krady MM, Moshkani S, Pal A, Almassian B, Rose JK, Robek MD, Nakaar V. Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B. Vaccines 2020, 8: 279. PMID: 32517032, PMCID: PMC7349932, DOI: 10.3390/vaccines8020279.Peer-Reviewed Original Research
2018
A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections
Chattopadhyay A, Aguilar PV, Bopp NE, Yarovinsky TO, Weaver SC, Rose JK. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections. Vaccine 2018, 36: 3894-3900. PMID: 29807712, DOI: 10.1016/j.vaccine.2018.05.095.Peer-Reviewed Original ResearchConceptsChikungunya virusZika virusA129 miceVesicular stomatitis virusChimeric vesicular stomatitis virusZika virus infectionWild-type miceSingle-dose vaccineRecombinant virus vaccineCo-circulating virusesLicensed vaccineSingle vaccinationZIKV infectionAntibody responsePandemic proportionsVirus vaccineVirus infectionAnimal modelsExperimental vaccinesVaccineMiceInfectionInvasive mosquito vectorsVSV glycoproteinVirus
2017
Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain
van den Pol AN, Mao G, Chattopadhyay A, Rose JK, Davis JN. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. Journal Of Virology 2017, 91: 10.1128/jvi.02154-16. PMID: 28077641, PMCID: PMC5331823, DOI: 10.1128/jvi.02154-16.Peer-Reviewed Original ResearchConceptsAdult mouse brainVesicular stomatitis virusVSV glycoprotein (G) geneAdult brainChimeric virusesOncolytic virusesVirus-like vesiclesChimeric vesicular stomatitis virusMouse brainSemliki Forest virusStomatitis virusPostnatal day 14 miceHealthy adult mouse brainRecombinant vesicular stomatitis virusKey immune mechanismsType I interferon responseG glycoproteinI interferon responseInterferon-stimulated genesDay 14 miceInfluenza H5N1 virusGlycoprotein geneNeurotropic natureIntranasal inoculationWild-type vesicular stomatitis virus
2013
Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters
Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Research 2013, 101: 26-29. PMID: 24184127, PMCID: PMC3874889, DOI: 10.1016/j.antiviral.2013.10.012.Peer-Reviewed Original ResearchConceptsFatal human encephalitisSingle-dose protectionReplication-defective vesicular stomatitis virusSafety profileLethal challengeSingle doseVirus vaccineEnhanced safety profileHuman encephalitisVaccine vectorVesicular stomatitis virusSyrian hamstersNiV fusionNipah virusBat reservoirsStomatitis virusAttachment glycoproteinHamstersVirusEncephalitisVaccineDose
2012
A Chimeric Vesiculo/Alphavirus Is an Effective Alphavirus Vaccine
Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. A Chimeric Vesiculo/Alphavirus Is an Effective Alphavirus Vaccine. Journal Of Virology 2012, 87: 395-402. PMID: 23077320, PMCID: PMC3536361, DOI: 10.1128/jvi.01860-12.Peer-Reviewed Original ResearchConceptsChikungunya virusVesicular stomatitis virusChimeric vesicular stomatitis virusAlphavirus vaccinesCellular immune responsesAlphavirus chikungunya virusMosquito-transmitted alphavirusCHIKV glycoproteinsCHIKV infectionCHIKV vaccineLicensed vaccineSingle doseWorldwide epidemicChikungunya feverImmune responseExperimental vaccinesAlphavirus infectionMultiple recent outbreaksVaccineHigh titersChimeric virusesSerious human diseasesVSV glycoproteinVirusRecent outbreak
2008
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection
Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 2008, 26: 6329-6337. PMID: 18832004, PMCID: PMC2628553, DOI: 10.1016/j.vaccine.2008.09.031.Peer-Reviewed Original ResearchConceptsTime of challengeVesicular stomatitis virusVaccine protectionAnti-LcrV antibodySingle-dose protectionDepletion of CD4Recombinant vesicular stomatitis virusYersinia pestis challengeCellular immunityAntibody titersSingle doseIgG1 isotypePlague vaccineLcrV proteinOptimal protectionPlague challengeCD4Stomatitis virusCellsCD8IgG2aVaccineMiceDoseTiters